KEAP1 and non-small cell lung carcinoma: Accordingly, the glutaminase inhibitor telaglenastat (CB-839) is being evaluated in phase II clinical trials, either in combination with chemo-immunotherapy or alone, in NSCLC patients whose tumors harbor KEAP1 or NFE2L2 mutations (NCT04265534 and NCT03872427).